Prime Medicine (PRME) Income from Continuing Operations (2021 - 2026)
Prime Medicine's (PRME) quarterly Income from Continuing Operations came in at 228713000.0 in Q1 2026, down 340.77% YoY from 94994257.48 in Q1 2025, and down 381.22% on a QoQ basis from 47528000.0 in Q4 2025.
Powered by 
Analysis
Prime Medicine (PRME) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Income from Continuing Operations data on file, last reported at 228713000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 340.77% year-over-year to 228713000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 453235000.0 (down 124.36% YoY) and the FY2025 annual result came in at 204204000.0, down 4.25% from the prior year.
- Income from Continuing Operations eased to 228713000.0 in Q1 2026, from 47528000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 23840000.0 in Q1 2022 to a low of 228713000.0 in Q1 2026.
- A 5-year average of 60056529.41 and a median of 47528000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 37.56% — and 2026, when it tumbled 340.77%.
- Tracing PRME's Income from Continuing Operations over 5 years: stood at 39283000.0 in 2022, then slumped by 67.1% to 65643000.0 in 2023, then soared by 35.6% to 42276000.0 in 2024, then dropped by 12.42% to 47528000.0 in 2025, then slumped by 381.22% to 228713000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 228713000.0 (Q1 2026), 47528000.0 (Q4 2025), and 124403000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Prime Medicine | 653.96 Mn | 653.96 Mn | - | -42.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.50 Mn |
| Mar 31, 2026 | -49.63 Mn |
| Dec 31, 2025 | -47.53 Mn |
| Sep 30, 2025 | -52.83 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.89 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.33 Mn |
| Mar 31, 2024 | -45.76 Mn |
| Dec 31, 2023 | -65.64 Mn |
| Sep 30, 2023 | -50.71 Mn |
| Jun 30, 2023 | -42.39 Mn |
| Mar 31, 2023 | -39.40 Mn |
| Dec 31, 2022 | -39.28 Mn |
| Sep 30, 2022 | -29.35 Mn |
| Jun 30, 2022 | -29.35 Mn |
| Mar 31, 2022 | -23.84 Mn |
| Dec 31, 2021 | -62.90 Mn |
| Sep 30, 2021 | -16.41 Mn |